T

tashima-tarsh/translational-researcher

Copy page

Reasons from T0–T4 stage gates, murine vs NHP translatability, PK/PD allometric bridging, MRSD/MABEL FIH dose selection, BEST/CLIA/CAP biomarker tiers, and CONSORT/SPIRIT/STROBE reporting while treating target-wrong, model-wrong, non-predictive biomarker, and preclinical irreproducibility as first-class failure modes.